Do you want to read an article? Please log in or register.
Comparative efficacy and safety of risankizumab versus ustekinumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis
Further Publications
Related content
Inflammatory Bowel Disease
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis
Adv Ther
Schreiber S, Danese S, Colombel JF, Hisamatsu T, Irving PM, Park H, Kim DH, Lee YN, Hanauer SB
doi: 10.1007/s12325-025-03447-6
Inflammatory Bowel Disease
Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study
J Crohns Colitis
Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK
doi: 10.1093/ecco-jcc/jjaf213
Inflammatory Bowel Disease
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial
J Crohns Colitis
Raine T, Danese S, Schreiber S, Gao X, Hanauer S, Torres J, Cunneen C, Kligys K, Huang X, Garrison A, Neimark E, Anschutz T, Crowley J, Cross RK
doi: 10.1093/ecco-jcc/jjag104
Inflammatory Bowel Disease
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg
J Crohns Colitis
De Greef E, Turner D, Kierkuś J, Korczowski B, Meglicka M, Cohen SA, Hyams JS, Griffiths AM, Rosh JR, Strauss R, Van Limbergen E, Adedokun OJ, Kim L, Volger S, UNITI Jr study Group
doi: 10.1093/ecco-jcc/jjag011
Inflammatory Bowel Disease
Efficacy, safety, and outcomes of endoscopic submucosal dissection for inflammatory bowel disease-associated colorectal neoplasia: a systematic review and meta-analysis comparing Asian and Western outcomes
J Crohns Colitis
Martins M, Nunes MV, Macedo G, Pioche M, Jacques J, Geyl S, Shimamura Y, Marques M, Lopes S, Cr Nunes A, Faria-Ramos I, Calabrese G, Sferrazza S, Rimondi A, Murino A, Despott E, De Sire R, Maselli R, Santos-Antunes J, Sousa-Pinto B, Morais R
doi: 10.1093/ecco-jcc/jjag082
Inflammatory Bowel Disease
Improvement in Health-Related Quality of Life in Patients With Moderate to Severe Crohn's Disease Treated With Risankizumab Versus Ustekinumab in the Phase 3B SEQUENCE Study
Am J Gastroenterol
Loftus EV Jr, Joshi N, Sands BE, Jairath V, Blumenstein I, Shukla N, Kligys K, Anschutz T, Griffith J, Zambrano J, Louis E
doi: 10.14309/ajg.0000000000004044
Inflammatory Bowel Disease
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial
Inflamm Bowel Dis
Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, Panés J, Van Rampelbergh R, Terry NA, Salese L, Vetter ML, Yee J, Corbett C, van Duijnhoven W, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI 1 investigators
doi: 10.1093/ibd/izag055
Inflammatory Bowel Disease
Intestinal ultrasound for the detection of postoperative recurrence in Crohn's disease: a systematic review and meta-analysis
J Crohns Colitis
Parra-Izquierdo V, Frías Ordoñez JS, Eggermont E, Verstockt B
doi: 10.1093/ecco-jcc/jjag094
RECOMMENDED
Inflammatory Bowel Disease
Efficacy of 5-Aminosalicylic Acid Continuation versus Discontinuation in Patients with Ulcerative Colitis Escalated to Advanced Therapy: A Systematic Review and Meta-Analysis of Adjusted Effect Estimates
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Sul HH, Gewehr DM, Kang H, Junior OR, Ungaro RC, Bernstein CN
doi: 10.1093/ecco-jcc/jjaf202